Durable responses seen with Amgen's KRAS-blocking cancer drug - STAT

Durable responses seen with Amgen's KRAS-blocking cancer drug - STAT

STAT Plus: Amgen’s KRAS-blocking cancer drug shows durable responses, with tempered expectations

By ADAM FEUERSTEIN

ANNE WESTON/FRANCIS CRICK INSTITUTE/WELLCOME

Lung cancer patients given sotorasib, Amgen's KRAS-blocking drug, lived a median of six months without their tumors worsening.

READ MORE